Evidence for Impact
Measuring the health and economic impact of 20 years of R&D investment for neglected diseases and emerging infectious diseases
More than US$60 billion was invested in R&D for neglected and emerging infectious diseases over the past 20 years. To understand the health and economic impact of these investments, we must identify and prioritize measures and indicators that assess the impact of new products and technologies. Join us on December 14th to discuss possible approaches to this challenge.
This official side event will provide a critical opportunity for the community to discuss progress across the innovation lifecycle, from product development to access to new medicines, and articulate the broad impact of R&D investment.
Date: Wednesday 14th December
Location: Kigali Convention Centre- Auditorium 1, Kigali, Rwanda
Time: 7:00 - 8:30am
- Dr Evelyn Gitau, Director of Research Capacity Strengthening, African Population Health Research Centre
- Dr Melinda Moree, Senior Program Officer, Bill and Melinda Gates Foundation
- Dr Nick Chapman, CEO, Policy Cures Research
- Dr Michael Makanga, Executive Director, European & Developing Countries Clinical Trials Partnership (EDCTP)
- Dr Noella Bigirimana (tbc), Deputy Director General, Rwanda Biomedical Centre
- Dr Nicaise Ndembi (tbc), Chief Science Advisor, Africa CDC
Breakfast will be provided from 6:30am onwards.
Please note: you must be registered for the 2nd International Conference on Public Health in Africa to enter the venue. If you are not attending the whole conference, you can purchase a one day registration for $50.